STAT+: What to know about Summit Therapeutics’ looming clinical trial readout
Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Summit Therapeutics’ China vs. U.S. data showdown
Dare I call it the most important study readout coming this summer? I’m referring to the pending announcement of the first clinical data from Summit Therapeutics and its buzzy PD-1-VEGF antibody ivonescimab derived from lung cancer patients in the U.S. and other Western countries.
At $17 billion, Summit is the most valuable development-stage biotech in the U.S. despite having no clinical data of its own. That’s an odd superlative to pin on a company, but ivonescimab is an unusual drug. It was invented by the Chinese drugmaker Akeso, and all the data presented to date — including evidence suggesting it may dethrone Merck’s Keytruda as the dominant cancer immunotherapy — have been generated from studies conducted by Akeso in China.
